TNFSF12 Antibody

What is TNFSF12 and what are its primary biological functions?

TNFSF12 (TNF superfamily member 12), commonly known as TWEAK, is a cytokine located on chromosome 17p13.1 that belongs to the tumor necrosis factor (TNF) superfamily. It binds to fibroblast growth factor-inducible 14 (Fn14, TNFRSF12A), activating the tumor necrosis factor receptor-associated factor (TRAF) signaling pathway and nuclear factor κB (NF-κB) signaling pathway. TNFSF12 performs various functions including angiogenesis regulation, modulation of cell proliferation, induction of apoptosis, tissue fibrosis, epithelial-mesenchymal transition (EMT), and immunomodulation. Its expression patterns vary across normal and pathological tissues, with differential regulatory effects depending on cellular context .

How do TNFSF12 antibodies function in research applications?

TNFSF12 antibodies are designed to specifically bind to TWEAK protein, allowing for detection, neutralization, or characterization of TWEAK in experimental systems. These antibodies can effectively neutralize TWEAK-mediated biological activities, such as its inhibitory effect on cell proliferation. For example, recombinant TWEAK can inhibit proliferation in human colon adenocarcinoma cell lines in a dose-dependent manner, and anti-TWEAK antibodies can neutralize this activity with typical neutralization doses (ND50) of 2-8 μg/mL for human TWEAK and 4-16 μg/mL for mouse TWEAK . In research settings, these antibodies are used for various techniques including immunohistochemistry, Western blotting, ELISA, immunofluorescence, and functional neutralization assays.

What are the structural characteristics of commercially available TNFSF12 antibodies?

Commercial TNFSF12 antibodies are typically raised against specific epitopes within the protein. For human applications, antibodies are often generated against E. coli-derived recombinant human TWEAK (Arg93-His249, Accession # Q4ACW9) . Similarly, for mouse studies, antibodies are frequently raised against recombinant mouse TWEAK/TNFSF12 (Arg105-His249, Accession # O54907) . These antibodies are most commonly available as polyclonal preparations, such as goat anti-human or anti-mouse TWEAK antigen affinity-purified polyclonal antibodies, although monoclonal options may also be available for specific applications.

How should researchers optimize TNFSF12 antibody dilutions for different experimental applications?

Optimization of TNFSF12 antibody dilutions requires systematic titration for each specific application and experimental system. For immunofluorescence applications, starting concentrations of approximately 10 μg/mL have been reported effective for detecting TWEAK in fixed cell lines, such as MDA-MB-231 human breast cancer cells . For neutralization assays, concentration ranges of 2-8 μg/mL for human TWEAK antibodies and 4-16 μg/mL for mouse TWEAK antibodies are typically reported as effective in the presence of 1-2 μg/mL of recombinant TWEAK protein . Researchers should perform preliminary experiments with a dilution series to determine optimal antibody concentrations for their specific cell types and experimental conditions, as optimal dilutions can vary significantly between applications and target cells.

What methods are most effective for detecting TNFSF12 expression in clinical samples?

Multiple methodologies can be employed for detecting TNFSF12 expression in clinical samples, each with specific advantages:

For clinical studies, ELISA has been successfully used to measure circulating TNFSF12 levels in breast cancer patients, with a reported detection range of 15.6 to 1000 pg/mL for human TNFSF12 . Interestingly, a trend toward lower serum levels of TNFSF12 has been observed in breast cancer patients compared to control subjects .

What controls should be included when using TNFSF12 antibodies in neutralization assays?

Proper controls are critical for accurate interpretation of TNFSF12 antibody neutralization assays:

• Isotype-matched control antibody: An irrelevant antibody of the same isotype and species (e.g., goat IgG specific for hen egg lysozyme) should be used at the same concentration as the anti-TWEAK antibody to control for non-specific effects .

• Dose-response curve: Establish a complete dose-response curve for recombinant TWEAK protein activity before testing neutralization .

• Untreated control: Include samples with no antibody treatment to establish baseline activity.

• Positive neutralization control: If available, include a validated neutralizing antibody with known efficacy.

• Genetic knockout validation: When possible, compare antibody neutralization results with data from TNFSF12 knockout models to confirm specificity of observed effects .

These controls help distinguish specific TWEAK neutralization from non-specific antibody effects or experimental artifacts.

What are the methodological approaches to study TNFSF12's role in tumor immune microenvironment?

Investigating TNFSF12's role in the tumor immune microenvironment requires integrated methodological approaches:

• Immune infiltration analysis: Single-sample gene set enrichment analysis (ssGSEA) can be applied to calculate infiltration levels of 24 immune cell types in relation to TNFSF12 expression. Research has shown that higher TNFSF12 expression correlates with increased proportions of CD8 T cells, cytotoxic cells, DCs, eosinophils, iDCs, mast cells, neutrophils, NK cells, and other immune cell populations .

• Tumor microenvironment scoring: Using the ESTIMATE algorithm to calculate stromal score, immune score, and estimate score based on gene expression patterns. TNFSF12 expression has been positively correlated with these scores in breast cancer .

• Immune checkpoint correlation analysis: Analyzing correlations between TNFSF12 expression and immune checkpoint genes to understand potential implications for immunotherapy response.

• Functional enrichment analysis: Performing Gene Set Enrichment Analysis (GSEA) to identify signaling pathways and biological processes associated with TNFSF12 expression levels in cancer.

• In vitro functional studies: Using anti-TWEAK antibodies to inhibit TWEAK signaling in cancer cell lines and analyzing effects on immune cell interactions.

How can researchers investigate the dual pro-invasive and anti-invasive effects of TNFSF12 in cancer models?

TNFSF12 exhibits context-dependent dual effects in cancer progression, showing both anti-invasive and pro-invasive properties depending on cellular conditions. To properly investigate these dual effects, researchers should:

• Characterize LCN2 expression: Since TNFSF12's effects depend on Lipocalin-2 (LCN2) expression, researchers should first quantify LCN2 levels in their experimental models using qRT-PCR, Western blotting, or immunohistochemistry .

• Perform invasion assays with TNFSF12 modulation: Use Transwell or 3D matrix invasion assays with recombinant TWEAK protein and anti-TWEAK neutralizing antibodies to assess invasion capacity under various conditions.

• Analyze signaling pathway activation: Examine activation of TRAF and NF-κB signaling pathways under TNFSF12 stimulation or inhibition using Western blotting for phosphorylated signaling proteins.

• Conduct genetic manipulation experiments: Compare results from antibody neutralization with TNFSF12 knockdown or knockout models to confirm pathway specificity.

• Assess epithelial-mesenchymal transition markers: Monitor EMT markers (E-cadherin, vimentin, etc.) in response to TNFSF12 modulation, as TNFSF12 is known to influence EMT processes.

• Establish co-culture systems: Develop co-culture systems with cancer cells and stromal/immune cells to better model the complex interactions in the tumor microenvironment that may influence TNFSF12's effects.

How do TNFSF12 antibodies help elucidate immune cell infiltration patterns in disease models?

TNFSF12 antibodies serve as valuable tools for investigating immune cell infiltration patterns through several methodological approaches:

• Immunohistochemistry and immunofluorescence: Anti-TNFSF12 antibodies can be used to visualize TWEAK expression patterns in tissue sections, allowing correlation with immune cell markers. This approach provides spatial information about the relationship between TWEAK expression and immune cell localization .

• Flow cytometry: Using fluorescently-labeled anti-TWEAK antibodies in combination with immune cell markers enables quantification of TWEAK expression on specific immune cell populations.

• In vivo neutralization studies: Administration of anti-TWEAK neutralizing antibodies (typically 10 mg/kg twice weekly) can block TWEAK signaling in disease models, allowing researchers to assess the impact on immune cell recruitment and activation .

• Comparative analysis with genetic models: Results from antibody-based studies can be compared with findings from TNFSF12 genetic deletion models (TNFSF12−/− or TNFSF12+/−) to validate observations and distinguish between developmental and acute effects .

• Time-course experiments: Administering anti-TWEAK antibodies at different disease stages helps determine temporal aspects of TWEAK's role in immune cell infiltration.

Research has shown that TNFSF12 expression levels correlate with infiltration of various immune cell types, including CD8 T cells, DCs, eosinophils, mast cells, neutrophils, and NK cells, suggesting its importance in shaping the immune landscape .

What is the role of TNFSF12 in atherosclerosis and how can antibodies help study this connection?

TNFSF12 plays a significant role in atherosclerosis development, and anti-TWEAK antibodies have been instrumental in elucidating these mechanisms:

• Intervention studies in established disease: Anti-TWEAK monoclonal antibodies (10 mg/kg twice weekly) administered to ApoE-deficient mice with established atherosclerotic lesions can help determine TWEAK's role in disease progression .

• Comparison with genetic deletion models: Contrasting the effects of anti-TWEAK antibody treatment with those observed in TNFSF12−/−ApoE−/− and TNFSF12+/−ApoE−/− mice provides complementary insights into acute versus developmental effects of TWEAK signaling in atherosclerosis .

• Control antibody validation: Using isotype-matched control antibodies (such as IgG specific for hen egg lysozyme) at equivalent doses ensures that observed effects are specifically due to TWEAK neutralization rather than non-specific antibody effects .

• Longitudinal assessment: Treatment protocols typically span several weeks (e.g., 16 weeks) to assess long-term effects on atherosclerotic plaque development and progression .

Studies utilizing these approaches have demonstrated that both genetic deletion of TNFSF12 and therapeutic administration of TWEAK-blocking antibodies can reduce atherosclerosis development, suggesting potential therapeutic applications for anti-TWEAK strategies in cardiovascular disease .

How can researchers address potential cross-reactivity and specificity issues with TNFSF12 antibodies?

Addressing specificity concerns with TNFSF12 antibodies requires rigorous validation approaches:

• Genetic knockout controls: Validate antibody specificity using tissues or cells from TNFSF12 knockout models, which should show no detectable signal with a specific antibody .

• Pre-absorption tests: Pre-incubate antibodies with recombinant TNFSF12 protein before application to determine if staining/detection is specifically blocked.

• Multiple antibody validation: Use multiple antibodies targeting different epitopes of TNFSF12 to confirm consistent results.

• Western blot validation: Confirm that antibodies detect bands of the expected molecular weight for TNFSF12 (~249 amino acids for the soluble form) .

• Comparison across species: When working with cross-species applications, carefully validate specificity for each species, as epitope recognition may vary despite sequence homology.

• Recombinant protein standards: Include concentration gradients of recombinant TNFSF12 protein in assays to establish detection limits and specificity.

• Negative control tissues: Include tissues known to express very low levels of TNFSF12 as negative controls in immunodetection experiments.

What factors influence the reproducibility of TNFSF12 antibody-based experiments?

Several critical factors affect reproducibility when working with TNFSF12 antibodies:

Researchers should document and standardize these variables across experiments to enhance reproducibility. For long-term studies, purchasing sufficient antibody from a single lot is recommended to eliminate lot-to-lot variation .

How do post-translational modifications of TNFSF12 affect antibody recognition and function?

Post-translational modifications (PTMs) can significantly impact TNFSF12 antibody recognition:

• Proteolytic processing: TWEAK exists in both membrane-bound and soluble forms following proteolytic cleavage. Antibodies may differentially recognize these forms based on epitope accessibility and preservation .

• Glycosylation effects: While E. coli-derived recombinant TWEAK used for antibody production lacks glycosylation, naturally occurring TWEAK may be glycosylated, potentially affecting antibody binding affinity or specificity .

• Conformational changes: Structural alterations in TWEAK due to experimental conditions (pH, reducing agents) may expose or mask epitopes, affecting antibody recognition.

• Multimerization status: TWEAK can form multimeric complexes that might influence epitope availability for antibody binding.

• Receptor binding interference: Consider whether antibodies targeting specific TWEAK domains might interfere with or be hindered by Fn14 receptor binding.

Researchers should carefully characterize which form of TWEAK their antibodies recognize and consider how sample preparation conditions might affect protein conformation and subsequent antibody detection.

How should researchers interpret contradictory findings between TNFSF12 antibody neutralization and genetic deletion experiments?

When faced with discrepancies between antibody neutralization and genetic deletion approaches, researchers should consider:

• Developmental versus acute effects: Genetic deletion affects the target throughout development, while antibody neutralization represents acute intervention. For example, in atherosclerosis studies, comparing TNFSF12−/−ApoE−/− mice with antibody-treated TNFSF12+/+ApoE−/− mice helps distinguish between these effects .

• Antibody specificity limitations: Antibodies may have off-target effects or incomplete neutralization. Comparison of multiple antibody clones and careful dose-response analysis can help address this issue.

• Compensation mechanisms in knockout models: Genetic knockouts may trigger compensatory expression of related molecules, confounding interpretations. Analyze expression of related TNF family members in knockout models.

• Cell-type specific effects: Antibodies may not equally penetrate all tissues, while genetic deletion affects all cell types. Consider cell-type specific conditional knockout approaches for more refined comparisons.

• Timing differences: Genetic deletion is present throughout life while antibody treatment typically has defined starting points. Time-course experiments with antibody administration at different stages can help resolve temporal aspects.

• Dosing considerations: Antibody neutralization may be incomplete at the doses used. Titration experiments with various antibody concentrations should be performed to establish dose-response relationships.

What statistical approaches are most appropriate for analyzing TNFSF12 expression data in relation to clinical outcomes?

For analyzing TNFSF12 expression in clinical contexts, several statistical approaches are recommended:

• Survival analysis: Kaplan-Meier survival curves with log-rank tests for comparing high versus low TNFSF12 expression groups. Cox proportional hazards regression for multivariate analysis incorporating clinical covariates .

• Expression comparison: Wilcoxon rank sum test or Kruskal-Wallis test for comparing TNFSF12 expression between tumor and normal tissues or across different clinical parameters (TNM stage, molecular subtypes) .

• Correlation analysis: Spearman's correlation method for assessing relationships between TNFSF12 expression and continuous variables such as immune cell infiltration levels or other gene expression values .

• ROC curve analysis: For evaluating the diagnostic potential of TNFSF12, using the area under the ROC curve to determine sensitivity and specificity at various expression thresholds .

• Stratification approaches: Dividing patients into high and low TNFSF12 expression groups based on median expression or optimal cutpoint determined by methods such as X-tile or maxstat.

• Multiple testing correction: Apply Benjamini-Hochberg or other appropriate methods to control false discovery rate when performing multiple comparisons.

For breast cancer specifically, stratification by molecular subtypes (PAM50) and hormone receptor status (ER, PR, HER2) has revealed subtype-specific associations between TNFSF12 expression and clinical outcomes .